CEO transition at Phathom: Steven Basta appointed, Terrie Curran resigns effective March 31, 2025

Phathom Pharmaceuticals, Inc.

Steven Basta appointed CEO, President and Class I director effective April 1, 2025; Terrie Curran resigned for personal reasons.
Basta receives $700k base salary, 70% target bonus, and initial option grant of 1,085,000 shares vesting over 4 years.
Basta also granted 360k stock-price-hurdle PSUs and 180k revenue-based PSUs (target) under new inducement plan.
Curran severance includes base salary through June 30, 2026, 2025 target bonus lump sum, COBRA, and accelerated vesting.
Board adopted 2025 Employment Inducement Incentive Award Plan reserving 2,500,000 shares without stockholder approval.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Terrie Curran

President and Chief Executive Officer

PHAT · Phathom Pharmaceuticals, Inc.

Effective: 2025-03-31
Successor: Steven Basta
Filed: April 1, 2025, 7:59 PM ET

Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.

Appointed

Steven Basta

Chief Executive Officer, President and Class I director

PHAT · Phathom Pharmaceuticals, Inc.

Effective: 2025-04-01
Filed: April 1, 2025, 7:59 PM ET

Steven Basta was appointed as the Chief Executive Officer, President and as a Class I director of Phathom Pharmaceuticals, Inc. (the “Company”), replacing Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Terrie Curran resigned as President and Chief Executive Officer at Phathom Pharmaceuticals, Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Basta was appointed as Chief Executive Officer, President and Class I director at Phathom Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer, President and Class I director

Exact text from the filing

Steven Basta was appointed as the Chief Executive Officer, President and as a Class I director of Phathom Pharmaceuticals, Inc. (the “Company”), replacing Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.

View on SEC.gov

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-069748

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.